The same study suggested that methylation of amino acid 162 was a negative predictive marker for anti-PD-1 treatment in patients with non-small-cell lung cancer, and methylated PD-L1/PD-L1 ratio was an accurate biomarker for predicting response to anti-PD-(L)1 therapy. The gene discussed is CD274; the disease is non-small cell lung carcinoma.